子宫内膜样腺癌术后辅助放化疗的临床观察  

Effect of postoperative adjuvant chemotherapy and radiotherapy on endometrial carcinoma

作　　者：安云婷[1] 李霞[1] 李隆玉[1] 李汉萍[1] 罗兵[1] 舒宽勇[1] 潘玫[1] 曾四元[1] 

机构地区：[1]江西省妇幼保健院肿瘤科,330006

出　　处：《中国妇产科临床杂志》2009年第3期186-188,共3页Chinese Journal of Clinical Obstetrics and Gynecology

摘　　要：目的评价有高危因素的子宫内膜样腺癌术后辅助放化疗的价值。方法选择宫颈侵犯、G3级、深肌层浸润、淋巴脉管侵犯、腹水细胞学阳性等高危因素的子宫内膜样腺癌268例,140例接受术后放疗,128例接受术后放化疗,比较两组的5年生存率。结果术后辅助放疗和术后辅助放化疗的5年生存率分别为92.14%和92.19%,两者比较,差异无统计学意义(P>0.05)。而两组的毒性反应比较,术后辅助放化疗组的毒性反应明显增加(P<0.05)。结论术后辅助盆腔放疗加化疗不能提高具有高危因素的子宫内膜样腺癌的5年生存率,且毒性反应明显增加。Objective To evaluate the effect of postoperative adjuvant chemotherapy or radiotherapy on highrisk endometfial carcinoma. Methods 268 patients who were in high risk factors of cervix invasion, G3, further muscular invasion, lymph node invasion, ascites cytology positive were observed. 140 patients of them were treated with surgery plus postoperative radiotherapy, 128 patients of them with surgery and postoperative adjuvant radiotherapy combined chemotherapy. The rate of 5 - year survival period and prognosis were analysed. Results The rate of 5 - year survival were 92.14% on the patients treated with surgery plus postoperative radiotherapy, the rate were 92.19% on surgery plus postoperative radiotherapy and chemotherapy, there was no significant difference of the rate of 5 - year survival in the two groups （P〉0.05）, while there was significant difference of the toxicity and secondary reaction in the two groups （P〈0.05）. Conclusion Postoperative pelvic radiotherapy plus chemotherapy can not increase the 5 - year survival rate in patients with high- risk endometrial carcinoma, and there may be more side effects.

关 键 词：子宫内膜样腺癌 术后放疗 术后放疗联合化疗 生存率 

分 类 号：R737.33[医药卫生—肿瘤] R737.14[医药卫生—临床医学]